Myeloproliferative Neoplasms Clinical Trials

8 recruiting

Myeloproliferative Neoplasms Trials at a Glance

18 actively recruiting trials for myeloproliferative neoplasms are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in New York, Chapel Hill, and Houston. Lead sponsors running myeloproliferative neoplasms studies include Incyte Corporation, UNC Lineberger Comprehensive Cancer Center, and Dr Andrew Parker.

Browse myeloproliferative neoplasms trials by phase

Treatments under study

About Myeloproliferative Neoplasms Clinical Trials

Looking for clinical trials for Myeloproliferative Neoplasms? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myeloproliferative Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myeloproliferative Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Myelofibrosis (MF)Polycythemia Vera (PV)Myeloproliferative Neoplasms (MPNs)
Prelude Therapeutics100 enrolled1 locationNCT07469891
Recruiting

MPN Childhood Registry

Childhood Myeloproliferative Neoplasms
University of Erlangen-Nürnberg Medical School500 enrolled1 locationNCT07410247
Recruiting
Phase 1

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corporation218 enrolled47 locationsNCT07441694
Recruiting
Phase 1

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corporation290 enrolled13 locationsNCT06034002
Recruiting
Phase 2

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center45 enrolled1 locationNCT06597734
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corporation186 enrolled31 locationsNCT06313593
Recruiting
Phase 1

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corporation120 enrolled26 locationsNCT07008118
Recruiting
Phase 1

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corporation225 enrolled29 locationsNCT05936359
Recruiting
Phase 1

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

Myeloproliferative Neoplasms
University of Chicago18 enrolled1 locationNCT06291987
Recruiting

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

LymphomaLeukemiaMyelodysplastic Syndromes+5 more
UNC Lineberger Comprehensive Cancer Center15,000 enrolled1 locationNCT01137643
Recruiting

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

LymphomaUnspecified Adult Solid Tumor, Protocol SpecificLeukemia+6 more
Barbara Ann Karmanos Cancer Institute1 locationNCT00935090
Recruiting

OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study

MDSMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms+1 more
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT06270771
Recruiting

Registry of Older Patients With Cancer

LymphomaUnspecified Adult Solid Tumor, Protocol SpecificLeukemia+6 more
UNC Lineberger Comprehensive Cancer Center3,000 enrolled7 locationsNCT01137825
Recruiting
Phase 2

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+13 more
Masonic Cancer Center, University of Minnesota300 enrolled1 locationNCT03314974
Recruiting
Phase 2

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

MDS (Myelodysplastic Syndrome)Acute Myeloid LeukaemiaMPN (Myeloproliferative Neoplasms)
Istituto Clinico Humanitas42 enrolled2 locationsNCT06892223
Recruiting
Phase 3

Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance

Myeloproliferative Neoplasms (MPN)
Siriraj Hospital240 enrolled1 locationNCT06740916
Recruiting
Phase 2

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis.

Myeloproliferative Neoplasms (MPN)Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Jubilant Therapeutics, Inc.30 enrolled3 locationsACTRN12624000478516
Recruiting

Determination of Calreticulin (CALR) mutation status based on peripheral blood immunohistochemistry and flow cytometry.

Myeloproliferative Neoplasms
Dr Andrew Parker20 enrolled1 locationACTRN12618000362291